These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 11680979

  • 1. [Hematopoietic stem cell transplantation with busulfanthiotepa-cyclophosphamide conditioning for pediatric patients with high-risk acute lymphoblastic leukemia].
    Umeda K, Lin YW, Watanabe K, Adachi S, Usami I, Akiyama Y, Kubota M, Nakahata T.
    Rinsho Ketsueki; 2001 Sep; 42(9):685-90. PubMed ID: 11680979
    [Abstract] [Full Text] [Related]

  • 2. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
    Worth L, Tran H, Petropoulos D, Culbert S, Mullen C, Roberts W, Przepiorka D, Chan K.
    Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
    [Abstract] [Full Text] [Related]

  • 3. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 4. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [Abstract] [Full Text] [Related]

  • 5. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 6. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
    Tang W, Wang L, Zhao WL, Chen YB, Shen ZX, Hu J.
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
    [Abstract] [Full Text] [Related]

  • 7. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Kröger N, Krüger W, Wacker-Backhaus G, Hegewisch-Becker S, Stockschläder M, Fuchs N, Rüssmann B, Renges H, Dürken M, Bielack S, de Wit M, Schuch G, Bartels H, Braumann D, Kuse R, Kabisch H, Erttmann R, Zander AR.
    Bone Marrow Transplant; 1998 Dec; 22(11):1029-33. PubMed ID: 9877263
    [Abstract] [Full Text] [Related]

  • 8. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 9. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
    Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D.
    Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
    [Abstract] [Full Text] [Related]

  • 10. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, Chen YH, Wang JZ, Han W, Lu DP.
    Chin Med J (Engl); 2007 Mar 20; 120(6):463-8. PubMed ID: 17439737
    [Abstract] [Full Text] [Related]

  • 11. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
    Przepiorka D, Khouri I, Thall P, Mehra R, Lee MS, Ippoliti C, Giralt S, Gajewski J, van Besien K, Andersson B, Körbling M, Deisseroth AB, Champlin R.
    Bone Marrow Transplant; 1999 May 20; 23(10):977-81. PubMed ID: 10373061
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia.
    Kang HJ, Shin HY, Choi HS, Han KS, Ahn HS.
    Bone Marrow Transplant; 2004 Mar 20; 33(5):471-6. PubMed ID: 14716339
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia].
    Matsuyama T, Kato K, Hanada R, Kawa K, Okamura J, Tsuchida M, Kigasawa H, Watanabe A, Hamamoto K, Kudoh T, Sano K, Ohira M, Hematopoietic Stem Cell Transplantation Study Group of Pediatric ALL.
    Rinsho Ketsueki; 2002 Jul 20; 43(7):527-37. PubMed ID: 12229121
    [Abstract] [Full Text] [Related]

  • 18. Mismatched T cell-depleted hematopoietic stem cell transplantation for children with high-risk acute leukemia.
    Aversa F, Terenzi A, Felicini R, Tabilio A, Falzetti F, Carotti A, Falcinelli F, Sodani P, Amici A, Zucchetti P, Mazzarino I, Martelli MF.
    Bone Marrow Transplant; 1998 Dec 20; 22 Suppl 5():S29-32. PubMed ID: 9989886
    [Abstract] [Full Text] [Related]

  • 19. Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia.
    Jacobsohn DA, Hewlett B, Ranalli M, Seshadri R, Duerst R, Kletzel M.
    Bone Marrow Transplant; 2004 Nov 20; 34(10):901-7. PubMed ID: 15361908
    [Abstract] [Full Text] [Related]

  • 20. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN, Young JW, Castro-Malaspina H, Prockop S, Wilton A, Heller G, Boulad F, Chiu M, Hsu K, Jakubowski A, Kernan NA, Perales MA, O'Reilly RJ, Papadopoulos EB.
    Biol Blood Marrow Transplant; 2007 Feb 20; 13(2):235-44. PubMed ID: 17241929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.